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Abstract 
We propose methods to determine the minimum number of subjects remaining at risk after which   
Kaplan-Meier survival plots for time-to-event outcomes should be curtailed, as, once the number 
remaining at risk drops below this minimum, the survival estimates are no longer meaningful in 
the context of the investigation. The size of the decrease of the Kaplan-Meier survival estimate 
S(t) at time t if one extra event should occur is considered in two ways. In the first approach, the 
investigator sets a maximum acceptable absolute decrease in S(t) should one extra event occur. In 
the second, a minimum acceptable number of subjects still at risk is calculated by comparing the 
size of the decrease in S(t) if an extra event should occur to the variability of the survival estimate 
had all subjects been followed to that time (confidence interval approach).  We recommend 
calculating both limits for the number still at risk and then making an informed choice in the 
context of the particular investigation. We explore further how the amount of information actually 
available can assist in considering issues of data maturity for studies whose outcome of interest 
is a survival percentage at a particular time point. 
We illustrate the approaches with a number of published studies having differing sample sizes 
and censoring issues. In particular, one study was the subject of some controversy regarding how 
far in time the Kaplan-Meier plot should be extended.  The proposed methods allow for limits to 
be calculated simply using the output provided by most statistical packages. 
 
 
Keywords: Kaplan-Meier curve, time-to-event, data maturity, percentage of actual information 
available, sensitivity index, follow-up, number at risk, data presentation. 
 
  
Data maturity and follow-up in time-to-event analyses 15 Dec 17 3 
 
Introduction and motivation 
For studies with time-to-event outcomes, the associated survival estimates need to account for 
censoring which occurs when individuals do not experience the event of interest during the period 
of their follow-up. The Kaplan-Meier method produces survival estimates S(t) at time t which are 
then displayed graphically as a Kaplan-Meier plot (survival curve)1, 2. This curve is a step 
function, decreasing each time an event is observed. It is used extensively in medicine and health 
sciences where time-to-event outcomes are common, and to illustrate data describing disease 
history available from clinical registries, to monitor the failure of medical devices, in areas of 
health economics and so on. A common application of the Kaplan-Meier approach is to obtain 
estimates and associated confidence intervals (CIs) of the probability of remaining event-free at 
specific time points. These estimates (a) help inform clinical practice and choice of therapy; (b) 
assist in evaluating new therapies; and (c) facilitate the evaluation of public health policies in 
relation to resources or directions required to reduce disease burdens in populations of interest. 
The uncertainty of a survival estimate increases as the number in the sample remaining at risk 
decreases over time. Survival estimates are often presented over the full duration of the follow-
up period, when more thought could be given to the value of the information displayed3-5, a point 
highlighted by Carter 6. Therefore, even though the estimates can be calculated, the question arises 
as to whether they should be included in the Kaplan-Meier plot?  In other words, how far in time 
should the Kaplan-Meier plot be extended? This question is directly related to the number of 
events which have been observed, and the extent of the study follow-up (data maturity).  
In prospective clinical trials, data maturity is one of the design parameters used to determine 
sample size. Ideally such studies do not report their results until the predetermined follow-up time 
is reached. The issue of data maturity is crucial in prospective and retrospective observational 
studies such as disease registries and epidemiological investigations, especially when the focus is 
the survival estimate at a clinically important time point. When long-term follow-up is of interest, 
and the evaluation time has not been pre-specified, a Kaplan-Meier plot should be curtailed before 
the number of subjects remaining at risk is too small to meaningfully interpret the survival 
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estimates. Guidelines regarding how far in time to extend the Kaplan-Meier plot would help to 
minimise interpretations which may be misleading. Pocock et al7, suggested “In general, we 
recommend that survival plots be halted once the  proportion of patients free of an event, but still 
in follow-up, becomes unduly small…. It will often be reasonable to curtail the plot when only 
around 10–20% are still in follow-up.” However, this guideline is problematic if the original study 
size is large: for example, 10-20% of a sample of 500 subjects corresponds to 50-100 subjects 
still at risk. Clark et al’s measure of data completeness8  provides an index of the actual follow-
up, which may be reduced by drop-out and censoring, relative to the expected follow-up if all 
subjects were accounted for to the end of the study. This index helps guide the interpretation of 
trial results. However in many observational cohorts, and especially clinical registries, the 
expected follow-up time for individuals in the cohort is unknown. To address some of the 
drawbacks relating to uncertainty and censoring, methods have been proposed to adjust the 
variance of the survival estimate to account for the reduction in the number at risk due to censoring 
resulting in modified variance estimators9-14. 
Apart from the issue of precision of the survival estimate when only a small number of subject 
are still at risk, the interpretation of the survival estimate may suffer from representiveness bias 
and compromise generalizability. For example, the trial of radioembolization for metastatic liver 
cancer in a high-risk patient cohort15 reported one patient (receiving the intervention) remaining 
disease free for over 8 years, while for all the other patients the disease-free survival (DFS) was 
< 5.5 years. Such a long DFS was considered extraordinary, but in subsequent similar studies with 
over 1000 (lower risk) patients and more modern chemotherapy16 a DFS of this magnitude could 
not be achieved. This individual was clearly atypical of this population and long term DFS rates 
based on this study would be misleading.  
A related question of data maturity is ‘For how long should subjects be followed once recruitment 
has been completed in studies whose primary outcome is the proportion of subjects remaining 
event-free at a particular time?’ This question often arises in studies of surgical techniques, organ 
transplantation, medical devices, paediatric therapies and radiotherapy where comparisons of 5 
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or 10-year survival rates are of more clinical interest than hazard ratios17-19. Consider, a study of 
adjuvant therapy after renal transplantation which has just completed accrual with the outcome 
being 5-year rejection-free survival. What proportion of patients should have completed 5-years 
follow-up, at the time of the analysis? Should the analysis wait until the last patient has reached 
5-year follow-up or can the data be analysed sooner, and if so, when? Achieving complete follow-
up may be inefficient and costly especially if only a small number of subjects were recruited in, 
say, the past 18 months. Prolonging follow-up to ensure the study achieves a 100% follow-up 
target may be impracticable or may have only a marginal impact on study results compared to 
those from an assessment at some earlier time. 
How far in time to extend the Kaplan-Meier survival plot 
Consider a sample of N subjects followed up over time until the event of interest occurs. Let S(t) 
denote the Kaplan-Meier event-free survival probability estimate at time t when n(t) subjects 
remain at risk. At time t=0, n(0)=N, S(0)=1 and subsequently decreases as events occur. If one 
extra event had occurred immediately after time t, then the decrease in the estimated percentage 
of subjects event-free would be Δ(t) where 
Δ(t) = 100S(t)/n(t)  is defined for n(t) ≥ 1. 
We will refer to Δ(t)=100S(t)/n(t) as the sensitivity index of the survival estimate at time t. 
If the estimated event-free survival probability at time t is high and few subjects remain at risk, 
then the sensitivity index will be large, indicating the potential for a sharp drop in the Kaplan-
Meier plot due to a single extra event. This is illustrated in figure 1 using data from the I-ELCAP 
study20, showing the survival outcomes of 484 asymptomatic patients with early stage lung cancer 
diagnosed through a screening program. The 10-year %survival estimate of 80% features 
prominently throughout the report. However, the sensitivity index at 10-years, shown as the thick 
dashed line, is 40% which is based on just two patients remaining at risk. This indicates a high 
sensitivity of the 10-year survival estimate to a single extra event which would drop the estimated 
80% survival to 40%. Dashed/dotted  arrows indicate the 10% and 20% number remaining at risk 
limits (at 60 and 72 months respectively) for extending the Kaplan-Meier plot suggested by 
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Pocock7.  The lower one-sided 95% confidence band developed by Fay, Brittain and Proschan11 
to account for increasing uncertainty due to the decreasing number at risk arising from censored 
follow-up is also displayed. 
// Figure 1 Kaplan-Meier plot for International Early Lung Cancer Investigators (I-ELCAP ) 
Study// 
We propose two approaches based on the sensitivity index Δ(t) for deciding when to curtail a 
Kaplan-Meier plot. Both produce a minimum number remaining at risk required to satisfy a 
particular criterion. We suggest using these values to decide on a suitable curtailment point in the 
context of the investigation. 
Criterion 1. Pre-defined sensitivity index threshold Δ* 
The first criterion sets a maximum acceptable decrease Δ* in the estimated percentage of subjects 
event-free should one extra event occur. That is, Δ(t) = 100S(t)/n(t)  <  Δ*, for all points displayed 
on the Kaplan-Meier plot. Therefore, for all t up to and including the curtailment time, 
n(t) > 100S(t)/ Δ*.     (1) 
This criterion is particularly helpful for studies exhibiting a high degree of ‘early’ censoring, 
(patients at risk not having sufficient follow-up over the study duration) as in the I-ELCAP 
study. When considering clinical practice or developing guidelines, Δ* should be small, <1% say 
(for example when using a clinical registry with large patient numbers). For other clinical 
studies (with ‘small’ or ‘moderate’ sample sizes) larger threshold values (2.5% or 5%) might be 
considered acceptable.  
Statistical packages routinely provide details of n(t) and S(t) at all censoring or event times t. 
The survival plot can be extended to t and satisfy Criterion 1 provided n(t) > 100S(t)/ Δ*. When 
the survival curve is close to the x axis, this issue may not be so important3, 21. 
 Criterion 2.  Δ(t) < width of one-sided 95% CI for %survival based on ‘full information’ 
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Criterion 1 however does not consider the uncertainty present in a survival estimate at the time 
point of interest, t. If there has been no censoring up to or including time t, then all N subjects 
enrolled in a study will have been followed up to or past time t. In this optimal situation of full 
information at time t, the standard error SE(t) of the estimate S(t) is smaller than if some censoring 
had occurred prior to time t. When there is full information at time t, SE(t) is simply the standard 
error of a binomial proportion S(t) with sample size N (the number of subjects entering the study), 
that is SE(t) = √{S(t)[1-S(t)]/N}. Furthermore, the lower boundary of the one-sided 95% 
confidence interval (CI) for the estimated percentage of subjects event-free in the case of full 
information at time t is 100*[S(t)-1.645*√{S(t)[1-S(t)]/N}] where 1.645 is the upper 5% quantile 
(often written z1-α) of the standard normal distribution. We refer to this boundary as the full 
information one-sided 95% confidence boundary of %survival. 
Our second criterion requires the sensitivity index Δ(t) to be no larger than the width of the full 
information one-sided 95%CI for the %survival at t, that is 
Δ(t) = 100*S(t)/n(t) ≤ 100*1.645*√{S(t)[1-S(t)]/N}, which gives 
1 ( )( )
1.645 1 ( )
NS tn t
S t
≥
−
.    (2) 
This criterion implies that one extra event observed just after time t would not decrease the 
estimated %survival to below its full information one-sided 95% confidence boundary at time t. 
We interpret this as evidence that enough subjects remain at risk at time t for the meaningful 
interpretation of the Kaplan-Meier plot.  
The relationship between the study size N and the minimum number at risk required to satisfy (2) 
is shown in figure 2 for S(t) =0.1,0.2, …, 0.95.  The different levels of S(t) reflect the different 
amounts of censoring present. Again, the quantities N and S(t) required in (2) are routinely 
produced by statistical packages. If a less conservative bound is desired for Criterion 2, the full 
information lower one-sided 97.5% CI can be used instead. In this case the divisor of 1.645 in (2) 
is replaced by 1.96. 
Data maturity and follow-up in time-to-event analyses 15 Dec 17 8 
 
//Figure 2 Minimum number of patients at risk satisfying Criterion 2 for different sample sizes 
N and selected values of the Kaplan-Meier curve S(t) from 0.1 to 0.95// 
 
Application to published studies 
Figure 1 (from reconstructed data12) shows the survival curve and the corresponding number at 
risk for 484 asymptomatic lung cancer patients. Of particular interest was the 120-month survival 
rate but quoting this rate when there were only 2 patients remaining at risk has received some 
discussion6, 12. Details of our approach are provided in table 1, which examines when the Kaplan-
Meier plot should be curtailed.  
   // Table 1: Number at risk of an event in the I-ELCAP lung study // 
 
In order to satisfy Criterion 2, the minimum number at risk at 84 months (shown by the solid 
vertical line in figure 1) is n ≥ 27 ={√484*[0.8/0.2]}/1.645.  This criterion is not satisfied for 
times after 84 months and extending the plot beyond this time would not be recommended. 
Additionally, the sensitivity index of the estimate at 84 months is 2.72% which, for this moderate 
sized study, appears reasonable. The 10-20% rule suggested by Pocock et al. would suggest 
curtailment at 59 or 72 months (indicated by the vertical dashed lines in figure 1) , when 96 or 48 
subjects are still at risk. 
A second example, the Continuous Positive Airway Pressure for Central Sleep Apnoea and Heart 
Failure (CANPAP) trial examined the effect of continuous positive airways pressure on heart 
failure22. The publication’s figure 3 shows the heart transplant-free survival curve out to 60 
months with an estimated transplant-free rate of 65% in the CPAP group (6 subjects still at risk) 
and 50% in the control with 4 subjects still at risk. The sensitivity index at 60 months is 11% for 
the CPAP group and 13% for the control group. The full information CI approach of Criterion 2 
suggests the curve be curtailed when there is a minimum of 10 intervention-group and 7 control 
patients at risk. If we also require the transplant-free estimate not to decrease by more than Δ*=5% 
in each group, the curve should be curtailed at 48 months, when S(48) = ~0.64 and n(48)=20 
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giving a sensitivity index of 3.2% in the CPAP, and S(48) = ~0.55 and n(48)=19 giving a 
sensitivity index 2.9% in the control group (the 48-month transplant rate is estimated at 55%).  
The third example, the MA 17 trial, the overall and disease-free survival in breast cancer patients 
receiving an additional 5 years of letrozole after 5 years of tamoxifen or placebo 23 was 
investigated with a sample size over 5000 patients. The Kaplan-Meier plots were extended to 48 
months, where less than 0.5% of patients were being followed up at this time. The results of these 
three studies are summarised in Table 2, together with how the approaches described here 
recommend where the Kaplan-Meier plots should be curtailed. 
// Table 2: Examples of published and recommended curtailment times // 
 
In all three cases, the Kaplan-Meier plots were extended much further than desirable from the 
information available, as measured by the number still at risk.  
Duration of follow-up after recruitment has completed  
The second data maturity issue, namely at what point during the follow-up phase of a study it 
would be appropriate to perform statistical analyses, is a concern in clinical studies whose 
outcome of interest is the survival proportion (or difference) at a pre-specified time t. As alluded 
to earlier the estimates at t also need to well reflect the patient population and not be unduly 
influenced by atypical patients. This issue becomes important particularly if (i) accrual has been 
prolonged; (ii) the cost of follow-up is substantial; (iii) the study result may have a major impact 
on clinical practice (e.g., evaluation of robotic surgery or implantation of a new medical device). 
Once a decision has been made to stop accrual into a study, the sample size is fixed. The only 
quantities which can then affect comparisons and robustness of a survival estimate at time t are 
the number of losses to follow-up and the number of events prior to t.  
We explore these issues of data maturity by considering the amount of actual information 
available. At any time t during a study one can determine; (i) the percentage of possible 
information available at the current point in the study and; (ii) the increase in in statistical power 
(from the current power if there was no further follow-up) for comparisons if follow-up were to 
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continue for all subjects up until the time point of interest (e.g. 5-year survival).  The variance of 
S(t) at time t, is simply SE(t)2. The ratio of the expected SE(t)2 of S(t), to the current SE(t)2 of S(t) 
(as calculated say, from Greenwood’s method24) may be used to quantify data maturity and 
provide a guide as to what could be expected if 100% complete follow-up at t were achieved. The 
expected SE(t)2 is obtained from [S(t)(1-S(t))/N*] where S(t) is the current survival estimate at 
time t and N* is the number of subjects who potentially can achieve full follow-up at time t (i.e., 
we may wish to exclude those patients who are lost to follow-up and will never be observed at t).  
This variance ratio will be expressed as a percentage and denoted I(t).  Clearly 0%≤ I(t) ≤ 100% 
and the smaller the ratio, the less mature the data. We note that the inverse of the ratio is 
sometimes referred to as the variance inflation ratio.  
The sample size for a study designs are typically based on 80% or 90% power and assume 
complete data at time t of interest. This power calculation is related to the probability of a type II 
error, β, and obtained from the quantiles of the standard normal distribution denoted by z1-β.  For 
90% power, z1-β =1.28 and for 80% power z1-β =0.84. The power for a comparison of two survival 
proportions can be calculated as Pr{Z < z(t)} where Z follows a standard normal distribution and 
z(t) = S(t)/SE(t). If we have incomplete data, z1(t) = z(t)√I(t). The power is fixed in advance 
(usually 90% or 80%), so z(t) is set at either 1.28 or 0.84. For a study with no further planned 
accrual and in follow-up, the potential power of any comparison, if performed at  the current study 
duration can be obtained by determining Pr{Z < z1(t)} from tables of the cumulative standard 
normal distribution. In the examples below, we will assume that all patients entering the study are 
available for follow-up to the time point of interest. 
To illustrate, the Z0011 trial examined the impact on 5-year survival of sentinel node biopsy 
(SNB) compared to auxiliary lymph node dissection (ALND) for women diagnosed with operable 
breast cancer 25 and aimed to enrol 1900 patients based on 90% power. The primary outcome was 
5-year overall survival and the sample size was obtained by assuming a non-inferiority margin of 
5% and a survival rate of 80% at 5-years, 4 years accrual and 5-years follow-up. The study closed 
early due to a low event rate, enrolling only 856 patients, after 5.6 years accrual and 5.1 years 
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follow-up and having a pooled 5-year survival rate of 92.2%. Based on this duration, a sample 
size of 856, a pooled 5-year survival rate of 92% and 5% non-inferiority margin, the power of the 
comparison has reduced from 90% to 67%. If we consider just the 420 patients allocated to 
ALND, the estimated 5-year rate was 91.8% (95% CI, 89.1%-94.5%) with 313 patients still at 
risk at this time and known not to have died. The expected SE(t)2 is (0.918*0.082)/420 and the 
SE(t)2  of the estimate at 5-years is 0.013782 giving I(5) = 94% with a similar result in the SNB 
group. Of the 52 deaths in this group, 32 deaths would be expected to have occurred prior to 5-
years, giving the rate of completeness of follow-up as 345/420= 82%. For 67% power, z1-β = 0.44 
and z1(t) = 0.44√0.94 so, performing the comparisons with the current follow-up would give a 
power of Pr{Z <0.426) or 66.5%, a minor decrease from 67%.  
While we have used just the ALND group to illustrate these ideas, in practice, all these quantities 
should only be obtained from pooled data (blinded to treatment allocation) to ensure no bias is 
introduced into the decision as to whether the data should be analysed at the current study 
duration. It is crucial that investigators and statisticians remain blinded to treatment allocation 
prior to these decisions being made. Decisions regarding study accrual/follow-up should be made 
prior to study commencement and decisions to stop a study prior to the accrual being met should 
be made by an independent data safety and monitoring committee who would assess the totality 
of the evidence before making their recommendations. Such committees would also review 
pooled data before requesting unblinded information.  
 We can also apply these ideas to the I-ELCAP study. The median follow-up for the observation 
group is 46 months (based on the reverse Kaplan-Meier method26) and, if the outcome of interest 
is the percentage of patients surviving at 72-months, the survival estimate is 81% with a variance 
of 0.02152. The full information variance at 72-months is (0.81*0.19)/484 (assuming no losses to 
follow-up), I(72) is 69% and I(120) is 41%. We note that 51 out of 410 patients (12.2%) not 
having an event have been followed to 72 months and 2 out of 409 (0.5%) have been followed to 
120 months. In this example where the prime interest in the precision of the S(t), the number at 
risk at t together with I(t) will help the interpretation of the maturity of follow-up at these times. 
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The change in the change in study power based on different levels of I(t) for study designs based 
power of 80% 85% and 90% is shown in figure 3. 
// Figure 3 Expected power for different levels of I(t) for studies initially designed to have 
90%, 85% and 80% power with full follow-up.// 
For studies with sample sizes based on power of 90%, I(t) as low as 45% would still provide 
adequate power (80%) for planned comparisons. 
We can use the number at risk as defined by criterion 1 or 2 together with the potential power of 
any planned comparisons (if appropriate), to provide a guide as to whether there is sufficient data 
maturity to stop follow-up. If at time t the actual number at risk satisfies the criteria (1 and/or 2) 
of choice, then this fact together with I(t) provides a guide as to the impact of stopping follow-
up at this time. For data from population registries where high precision of the estimates is 
required, n(t) should satisfy criterion 1 together with a high value of I(t) to ensure the robustness 
of the published estimates. 
Discussion 
Two related problems associated with data maturity in clinical studies having time-to-event 
outcomes have been explored; (i) difficulty of drawing sensible conclusions from published 
displays where the survival estimate is sensitive to an extra event making clinical decisions 
difficult; and (ii) how much follow-up on completion of study recruitment is required prior to 
reporting of the study results. While much of the focus has been on the impact of the number at 
risk and the precision of the survival estimate at time t the issue of how well these patients 
represent the disease population should also be considered. Survival curves extended to the last 
known event time (so called “all the way”7, a view held by many investigators) may well be 
misleading, cloud interpretation and compromise the generalisability of the study.   
We defined the sensitivity index Δ(t) of the Kaplan Meier estimate S(t) at a t, as the decrease of 
the %survival estimate had one extra event occurred immediately post t. We propose two criteria 
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to assess Δ(t). The first sets a maximum acceptable threshold Δ* for the sensitivity index in the 
context of the investigation. The second criterion restricts Δ(t) to be no larger than the width of 
the full information one-sided 95% CI for the %survival at t. These approaches assist investigators 
in deciding when to curtail the Kaplan-Meier plot and so avoid potential misrepresentation of the 
survival estimates. The 95% confidence interval at t is commonly obtained from Greenwoods 
formula but this approach has limitations 9, 12. When compared to the recommendation of Pocock7, 
the proposed strategies are less conservative.  
More recently Fay et al.11 have proposed a method which adjusts the width of the confidence 
interval to account for changes in the number at risk based on the product of beta random 
variables.  While the method is methodologically complex, with calculations currently only 
available in the statistical package R, it nevertheless illustrates the increase in uncertainty with 
increased censoring. However, when there are multiple curves being presented (as in the ADAPT 
study27), the benefit of the visual representation can be masked with the multiple confidence 
bands. Fay et al’s lower one-sided 95% CI is shown as the shaded area in figure 1; the lower limit 
at 120 months being 0.21 and, at 84 months, 0.70. These values are larger than 0.76, the value 
given at both times by the Greenwood method. While these intervals demonstrate the uncertainty 
in the estimates they do not provide guidelines as to when survival plots should be curtailed. Our 
approach provides a framework for interpretation of survival estimates at specified time points 
based on both the uncertainty and the number at risk at these points.  
This approach has applicability to a wide range of practical problems, and does not rely on 
assumptions of specific censoring patterns of the trial or the extent of censoring present in the 
data. These guidelines have applications in deciding on the time point at which the tail of the 
survival curve should be modelled in studies of cost-effectiveness and quality-adjusted survival. 
With registry or population information, the sensitivity index of the Kaplan-Meier plot to 
individual events should be low. Such precision is demanded by health decision makers when 
establishing policy guidelines. When interventions are evaluated for effectiveness over long 
periods (radiotherapy, surgical procedures, and implanted devices), it is essential the disease or 
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device failure-free rates at 3, 5, or 10 years are not sensitive to an additional event. In these cases, 
the decrease Δ(t) in the % survival if one extra event were to occur should be small (1% or, at 
most 2.5%) to provide reasonable precision boundaries. Different levels of precision may be 
desired/warranted depending on the problem being investigated. 
The second problem related to data maturity, examines the completeness of follow-up once 
accrual to a study has finished. This is based on the amount of actual information available relative 
to having complete follow-up at time t. We use this quantity to calculate the potential statistical 
power of any comparisons providing a guide as to whether an individual study has sufficient data 
maturity at the current duration of follow-up.    
Bias induced by differential censoring has been studied by Beltangady et al for the log-rank test28 
and by Persson et al 29 for the proportional-hazards model. This supports the need for guidelines 
for (a) when survival estimates should be quoted and when the corresponding comparisons of 
these estimates at key time-points can sensibly be performed, and (b) how much follow-up should 
be planned. These issues are crucial when reporting results of observational studies, especially 
from population disease registries or clinical databases which provide rates of clinical benefit or 
toxicities etc., to inform future studies or help formulate public health policy.  
Conclusion 
We provide a simple and effective framework to gauge the maturity of data at different follow-
up times to inform researchers as to which follow-up time provides sufficient information to allow 
sensible interpretation of survival estimates. Two approaches for when to curtail the Kaplan-
Meier plot are proposed, both related to the decrease in the %survival estimate if one further event 
were to occur. The minimum required number at risk at any time point based on the full 
information CI has a straightforward interpretation and can be easily calculated from the output 
provided by common statistical packages.  We provide an approach to ascertain the actual 
information based on the current number of events and current follow-up times in a clinical study. 
This allows investigators to determine the statistical power certain comparisons may have if 
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analyses were performed at this time. For non-comparative studies the percentage of actual 
information will help inform whether follow-up is sufficient or needs to be prolonged. 
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Key Messages 
• The information provided by the Kaplan-Meier (KM) curve at a particular time point is dependent 
on the number of subjects at risk at this time point. If there are only a few patients at risk, then 
one single extra event will make a substantial impact on the distance by which the KM curve 
decreases. 
 
• Data maturity is explored with respect to two problems: (i) how far in time a KM curve should be 
extended and (ii) at what point in a clinical study, prior to achieving complete follow-up, can it 
still be appropriate to report results.   
 
•  For (i), a minimum desirable number at risk is readily obtained if the drop in the survival estimate 
at time t should one extra event occur is required to be less than a pre-determined threshold. To 
ensure this drop remains below the threshold, large survival estimates require more patients 
remaining at risk than smaller ones. 
 
• An alternative approach to (i) is to require that the decrease in the survival estimate at time t 
should one extra event occur does not exceed the width of the one-sided 95% CI for survival based 
on ‘full information’ if all the data were available up to the time of interest.   
 
• For (ii), when follow-up is incomplete at some time point, the variance of the KM estimate is larger 
than if there had been complete follow-up. The variance ratio represents the proportion of actual 
information available at the time point. It can be used in comparative studies to determine the 
potential statistical power if study results are reported for that time point without further follow-
up. 
 
• The amount of current information available and the percentage of complete follow-up can be 
used to both plan the follow-up duration of the current study to ensure that a study attains an 
acceptable level of actual information or sufficient expected power prior to analysis of the results.  
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Figure legend 
 
Figure 1  
Kaplan-Meier plot for International Early Lung Cancer Investigators I-ELCAP Study.   
          The impact on the estimate if one extra event at 120 months were to occur 
Curtail the plot the 20% (60 months) point (Pocock rule) 
           Curtail the plot the 10% (72 months) point (Pocock rule) 
Curtailment point for the full follow-up one-sided 95% CI criteria (84 months). 
Shaded area: Fay and Brittain 95% one-sided pointwise confidence bands 
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Figure 2  
Minimum number of patients at risk for different sample sizes for values of the Kaplan-Meier 
curve, S(t) from 0.1 to 0.95 
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Figure 3 
Levels of statistical power for percentages of actual information available in study designs 
having 80%, 85% and 90% power with complete information 
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Table 1: Number at risk of an event in the I-ELCAP lung study  
Time 
Survival 
estimates 
Actual number 
at risk (nr) 
Minimum n satisfying 
criretrion 2 
decrease in the %survival 
estimate for one extra event‡ 
0 1.00 484  0.21 
6 0.98 456 87 0.21 
12 0.95 434 58 0.22 
18 0.92 390 45 0.24 
24 0.88 357 37 0.25 
30 0.86 322 34 0.27 
36 0.84 281 31 0.30 
42 0.84 236 31 0.35 
48 0.82 184 29 0.45 
54 0.82 133 29 0.62 
62 0.81 91 28 0.89 
66 0.81 67 28 1.21 
72 0.81 51 28 1.59 
78 0.81 41 28 1.97 
84 0.79 29 26* 2.72† 
90 0.79 21 26 3.76 
96 0.79 16 26 4.93 
102 0.79 11 26 7.17 
108 0.79 9 26 8.77 
114 0.79 7 26 11.27 
120 0.79 2 26 39.50 
*Number at risk according to criterion 2 required for extending the survival curve based on full 
information. If this minimum is larger than the actual number at risk, then not extending the 
curve past this time point should be considered 
†26 = 
1 484 * (0.79)
1.645 (1 0.79)−
  
‡100*(0.79/29)% is the decrease in the % survival;estimate if one extra event were to occur at 
84 months.  
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Table 2: Examples of published and recommended curtailment times. 
Study I-ELCAP  CANPAP  MA 17  
Outcome Overall 
survival 
Transplant-free 
survival Disease-free survival 
  CPAP Control Control Letrozole 
Published study results      
Total sample size 484 128 130 2582 2575 
Curtailment time 120 months 60 months 48 months 
At published curtailment time     
100S(t) 80% 65%* 50%* 83%* 93%* 
Number at risk 2 6 4 11 9 
Sensitivity index‡  40% 11% 13%   8% 10% 
Recommended curtailment time     
Minimum number at risk 
based on Criterion 2 
27 10 7 71 149 
Corresponding curtailment 
time (months) 
84  48  42†*  
Sensitivity index 2.72% 3.2% 2.9% 0.66% 0.64% 
Pocock’s 10% (20%) rule      
Number at risk from the 10% 
(20%) rule 
48 (97) 13 (26) 258 (516) 
Curtailmant time (months) at 
10% (20%) 
72 (60) 54(42)  38(32) 
† assumes uniform attrition between 40 and 50 months of 17 patients per month in each group; 
S(42) = 0.96 for Letrozole and S(42)= 0.85 for control 
*Estimated from the published figure. 
‡ at the published curtailment time  
 
 
 
 
 
